|
UMIN-CTR History |
|
 UMIN-CTR English Home |
Glossary (Simple) |
FAQ |
Search clinical trials |
| Name: | UMIN ID: |
| Unique ID issued by UMIN | UMIN000026961 |
| Receipt No. | R000030917 |
| Scientific Title | An Open label Phase I Study to Evaluate the Safety and Efficacy of OBP-301 with Pembrolizumab in Patients with advanced solid tumors. |
| Date of disclosure of the study information | 2017/07/31 |
| Last modified on | 2020/04/14 09:07:14 |
| No. | Disposal | Last modified on | Item of update | |
| 1 | Insert | 2017/04/12 15:25:37 | ||
| 2 | Update | 2017/04/28 13:33:48 | Date of disclosure of the study information |
|
| 3 | Update | 2017/05/12 10:34:54 | Date of disclosure of the study information |
|
| 4 | Update | 2017/05/12 10:36:26 | Date of protocol fixation Anticipated trial start date |
|
| 5 | Update | 2017/05/12 13:23:42 | Key inclusion criteria |
|
| 6 | Update | 2017/10/13 15:14:06 | Recruitment status Anticipated trial start date |
|
| 7 | Update | 2017/10/13 15:15:09 | Institutions |
|
| 8 | Update | 2018/11/29 11:41:08 | Interventions/Control_1 Interventions/Control_1 |
|
| 9 | Update | 2019/10/15 08:41:52 | 1st name of lead principal investigator Last name of lead principal investigator 1st name of lead principal investigator Last name of lead principal investigator Zip code Address Last name of contact person Last name of contact person Zip code Organization Organization Address Address Tel |
|
| 10 | Update | 2019/10/15 08:44:28 | Date of IRB Last follow-up date |
|
| 11 | Update | 2020/04/14 09:05:38 | Target sample size |
|
| 12 | Update | 2020/04/14 09:07:14 | Last follow-up date |
